Yahoo
Paris - Delayed Quote EUR

Vetoquinol SA (VETO.PA)

85.00 -3.50 (-3.95%)
At close: October 30 at 5:35:05 PM GMT+1
Chart Range Bar
Loading chart for VETO.PA
  • Previous Close 88.50
  • Open 86.90
  • Bid --
  • Ask --
  • Day's Range 85.00 - 89.50
  • 52 Week Range 65.70 - 91.50
  • Volume 8,435
  • Avg. Volume 9,623
  • Market Cap (intraday) 988.093M
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) 15.62
  • EPS (TTM) 5.44
  • Earnings Date Sep 10, 2026
  • Forward Dividend & Yield 0.93 (1.09%)
  • Ex-Dividend Date Jun 3, 2026
  • 1y Target Est 91.66

Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.

www.vetoquinol.com

2,526

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

VETO.PA
3.19%
CAC 40 (^FCHI)
2.21%

1-Year Return

VETO.PA
16.43%
CAC 40 (^FCHI)
2.30%

3-Year Return

VETO.PA
12.28%
CAC 40 (^FCHI)
16.77%

5-Year Return

VETO.PA
39.48%
CAC 40 (^FCHI)
16.68%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 139.7M
Earnings --
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
0.0%

Analyst Insights

View More

Analyst Price Targets

80.00 Low
91.66 Average
85.00 Current
110.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.91%

  • Return on Assets (ttm)

    7.04%

  • Return on Equity (ttm)

    10.68%

  • Revenue (ttm)

    527.34M

  • Net Income Avi to Common (ttm)

    62.83M

  • Diluted EPS (ttm)

    5.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    235.2M

  • Total Debt/Equity (mrq)

    2.03%

  • Levered Free Cash Flow (ttm)

    72.82M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: